# Azis Rafael Dabas — Executive Profile and Writing I am Azis Rafael Dabas, a healthcare executive, founder and strategic growth advisor based in New York. My operating record spans specialty pharmacy, kidney-care networks, multispecialty claims intelligence and behavioral-health growth. I connect enterprise strategy and P&L ownership with payer-provider partnerships, market expansion and care capacity. Through Maison Dabas Consulting, I develop commercialization plans, financial models and operating designs. In my writing, I examine where a healthcare thesis creates value, which institution can capture it, and what must change operationally for the investment to work. Name variants: Azis Rafael Dabas; Azis R. Dabas; Azis Dabas. Canonical author identity: https://azisdabas.com/profile/#azis-dabas ## Core reading routes - [Executive profile and evidence-linked capabilities](https://azisdabas.com/profile/) - [Operating record](https://azisdabas.com/work/) - [Strategic perspective](https://azisdabas.com/strategy/) - [Original operating blueprints](https://azisdabas.com/blueprints/) - [Connected-care framework](https://azisdabas.com/whole-care/) - [Illustrative executive economic models](https://azisdabas.com/healthcare-economics/) - [Research and evidence](https://azisdabas.com/research/) - [All 102 articles](https://azisdabas.com/insights/) - [Full-text executive reading collection](https://azisdabas.com/llms-full.txt) - [Structured article catalog](https://azisdabas.com/knowledge-index.json) ## Executive scope and supporting evidence ### Enterprise strategy and capital allocation Operating experience + original analysis. My founder P&L responsibilities connected market choice to purchasing, inventory, staffing, reimbursement and working capital. I apply that discipline to capital allocation: identifying the commitment an opportunity requires, the downside it creates and the evidence needed before making it permanent. - [Founder operating case](https://azisdabas.com/work/pharmacy-platform/) - [CFO economics](https://azisdabas.com/insights/cfo-economics-accountable-access/) - [Capital allocation](https://azisdabas.com/insights/healthcare-capital-allocation-under-uncertainty/) ### Growth, commercialization and distribution Operating experience + original analysis. I assess market expansion through addressable demand, purchasing authority and the capacity to serve. Segmentation and referral development matter when they produce business the organization can deliver at acceptable contribution, implementation cost and cash requirements. - [Behavioral-health growth case](https://azisdabas.com/work/behavioral-health/) - [Provider network growth](https://azisdabas.com/insights/provider-network-growth-strategy/) - [Commercial operating system](https://azisdabas.com/insights/healthcare-gtm-operating-system/) ### Payer-provider partnerships and benefit economics Operating experience + original analysis. My pharmacy experience includes Medicare Part D, Medicaid managed care, commercial PBM and PSAO relationships. I examine a partnership from both sides of the contract: how coverage and payment affect access, which party funds the enabling work, and whether the distribution of value can sustain delivery. - [Payer and pharmacy operations](https://azisdabas.com/work/pharmacy-platform/) - [Part D continuity](https://azisdabas.com/insights/medicare-part-d-affordability-continuity-strategy/) - [Medicaid continuity](https://azisdabas.com/insights/medicaid-eligibility-continuity-economics-2027/) ### Provider networks, population health and quality Operating experience + original strategy design. My kidney-network and multispecialty work connects referral demand to intake, facility readiness and service-line priorities. In my regional-network blueprint, I extend that analysis to population accountability: which entity owns a care gap, how performance is evidenced, and how resources move when the network cannot deliver. - [Kidney-network operating case](https://azisdabas.com/work/dialysis-network/) - [Claims-intelligence operating case](https://azisdabas.com/work/claims-intelligence/) - [Regional network blueprint](https://azisdabas.com/blueprints/regional-healthcare-network-performance-value-integration-blueprint/) ### Pharmacy, therapeutics and medication access Operating experience + original research analysis. I have owned the operating decisions behind a specialty-pharmacy business, including payer access, purchasing, dispensing automation, patient service and financial control. My therapeutics analysis follows the same economic chain from acquisition and reimbursement to patient access, persistence and the cost of unresolved exceptions. - [Specialty-pharmacy commercialization](https://azisdabas.com/insights/specialty-pharmacy-commercialization/) - [Biosimilar economics](https://azisdabas.com/insights/biosimilar-benefit-design-procurement-economics/) - [Drug shortage resilience](https://azisdabas.com/insights/drug-shortage-resilience-capital-allocation/) ### Kidney, cardiometabolic and chronic-care pathways Operating experience + original research analysis. My kidney-care experience grounds my analysis of access, admissions and treatment capacity. I examine prevention and chronic-care investment through the relevant time horizon, delivery burden and distribution of benefit, keeping clinical evidence separate from the institution’s near-term financial return. - [Precision CKM allocation](https://azisdabas.com/insights/precision-ckm-equity-pathway-allocation/) - [GLP-1 cardiorenal economics](https://azisdabas.com/insights/glp1-cardiorenal-outcome-contract-economics/) - [Institutional metabolic blueprint](https://azisdabas.com/blueprints/institutional-metabolic-health-growth-blueprint/) ### Behavioral health and service-line capacity Operating experience + original research analysis. My behavioral-health growth work connects clinician supply, payer coverage, acquisition, intake and scheduling. I assess expansion against the capacity required to sustain care after enrollment, including the financial consequences of unused appointments, delayed treatment and unbalanced service-line demand. - [Behavioral-health operating case](https://azisdabas.com/work/behavioral-health/) - [Integrated care operating model](https://azisdabas.com/insights/behavioral-health-population-operating-model/) - [Longitudinal integration evidence](https://azisdabas.com/insights/behavioral-health-maintenance-evidence/) ### Social needs, public health and nutrition benefits Original strategy design + research analysis. In my proposed whole-care architecture, social support is a service that needs capacity, funding and accountability. My nutrition and population-health analyses distinguish offering a benefit from delivering an intervention, then examine whether the contract funds the work and reaches the intended population. - [Population benefit](https://azisdabas.com/insights/population-health-allocation-public-value/) - [Food-as-medicine contracts](https://azisdabas.com/insights/food-as-medicine-contracting-persistence-evidence/) - [Nutrition payer blueprint](https://azisdabas.com/blueprints/nutrition-benefits-payer-access-completed-care/) ### Data, claims intelligence and interoperability Operating experience + original analysis. I use claims intelligence to translate utilization, geography and provider behavior into service-line priorities and field decisions. My analysis of interoperability and quality measurement asks whether the data is sufficiently complete, attributable and timely to support the decision or financial obligation attached to it. - [Claims-intelligence work](https://azisdabas.com/work/claims-intelligence/) - [Interoperability and distribution](https://azisdabas.com/insights/interoperability-commercial-distribution/) - [Digital quality infrastructure](https://azisdabas.com/insights/digital-quality-measurement-contracting-infrastructure/) ### Governed AI, revenue operations and value realization Operating designs + original analysis. I evaluate automation through the operating change it makes possible and the total cost of maintaining it. Across revenue cycle, payment integrity and clinical workflows, my analysis follows the path from task performance to review burden, usable capacity and value the purchaser can actually retain. - [Governed AI architecture](https://azisdabas.com/insights/healthcare-ai-control-plane-whole-system/) - [Revenue integrity](https://azisdabas.com/insights/agentic-revenue-integrity-control-plane/) - [AI value realization](https://azisdabas.com/insights/healthcare-ai-value-realization-ledger/) ### Whole-care orchestration, sensing and closure Proposed frameworks + research analysis. My 16-domain whole-care framework examines the dependencies among clinical services, pharmacy, behavioral health, social support and financing. My sensing analyses distinguish a measured signal from a confirmed need, then test whether interpretation and response capacity justify adding that signal to care. - [Sixteen-domain framework](https://azisdabas.com/whole-care/) - [Whole-care orchestration](https://azisdabas.com/insights/whole-care-orchestration-strategy/) - [Wireless sensing evidence](https://azisdabas.com/insights/wireless-sensing-whole-care-evidence/) ### Specialty, home, rural, women’s and family-care strategy Original research analysis + proposed architectures. My research spans oncology, precision diagnostics, dementia, acute and post-acute care, rural health, and women’s and family care. I examine the institutional choice within each setting: what to finance, where responsibility should sit and what evidence supports expansion. These are research analyses and proposed architectures, distinguished from my operating history. - [Precision oncology](https://azisdabas.com/insights/precision-oncology-treatment-pathway/) - [Post-acute capacity](https://azisdabas.com/insights/post-acute-capacity-portfolio-contracting/) - [Women’s midlife health](https://azisdabas.com/insights/womens-midlife-health-integrated-care-employer-strategy/) - [Rural health](https://azisdabas.com/insights/rural-health-transformation-capacity-capital-workforce/) - [Dementia household capacity](https://azisdabas.com/insights/dementia-care-household-capacity/) ## Editorial context Operating outcomes are self-reported and retain their qualification on the source pages. Blueprints and architectures are original proposed designs. Articles are executive analyses and research syntheses, not peer-reviewed journal publications or original clinical studies. Cited researchers retain authorship. Model outputs are illustrative scenarios. No university, journal or investment-firm endorsement is implied. The source pages contain the evidence boundaries and citations. ## Operating cases and proposed designs - [Build the business behind the prescription.](https://azisdabas.com/work/pharmacy-platform/) — Self-reported operating experience. - [The data lake becomes useful at the next decision.](https://azisdabas.com/work/claims-intelligence/) — Self-reported operating experience. - [A referral is only valuable when care can begin.](https://azisdabas.com/work/dialysis-network/) — Self-reported operating experience. - [Growth has to fit the capacity to deliver care.](https://azisdabas.com/work/behavioral-health/) — Self-reported operating experience. - [Institutional Metabolic Health: A Growth and Value-Creation Blueprint](https://azisdabas.com/blueprints/institutional-metabolic-health-growth-blueprint/) — Original proposed strategy design. - [Nutrition Benefits: From Payer Access to Completed Care](https://azisdabas.com/blueprints/nutrition-benefits-payer-access-completed-care/) — Original proposed strategy design. - [Regional Healthcare Network Blueprint: Population Health, Performance and Value Integration](https://azisdabas.com/blueprints/regional-healthcare-network-performance-value-integration-blueprint/) — Original proposed strategy design. - [Government Payment Integrity Control Plane](https://azisdabas.com/case-studies/government-payment-integrity-control-plane/) — Original proposed operating architecture. - [Dementia Care / GUIDE GTM System](https://azisdabas.com/case-studies/guide-dementia-gtm/) — Original proposed operating architecture. - [Healthcare Venture Formation](https://azisdabas.com/case-studies/healthcare-venture-formation/) — Original proposed operating architecture. - [Medicaid Nutrition Activation OS](https://azisdabas.com/case-studies/medicaid-nutrition-activation-os/) — Original proposed operating architecture. - [Pediatric Quality Infrastructure](https://azisdabas.com/case-studies/pediatric-quality-infrastructure/) — Original proposed operating architecture. - [Reimbursement Infrastructure](https://azisdabas.com/case-studies/reimbursement-infrastructure/) — Original proposed operating architecture. - [Specialty Infusion Market Intelligence](https://azisdabas.com/case-studies/specialty-infusion-market-intelligence/) — Original proposed operating architecture. ## Complete article index - [Women's Midlife Health Needs an Integrated Delivery Strategy](https://azisdabas.com/insights/womens-midlife-health-integrated-care-employer-strategy/) — 2026-10-07: An executive framework connecting menopause care, cardiometabolic prevention, behavioral health and employer benefits with measurable, private follow-through. - [The Part D redesign has to reach the medication journey](https://azisdabas.com/insights/medicare-part-d-affordability-continuity-strategy/) — 2026-10-07: Connect Medicare Part D benefit design to medication affordability, payment timing and the operating economics of continuity across care and pharmacy. - [Rural Health Transformation Is a Capacity and Capital Strategy](https://azisdabas.com/insights/rural-health-transformation-capacity-capital-workforce/) — 2026-10-07: How rural health leaders can turn federal transformation funding into durable clinical capacity, stronger referral networks and sustainable local care. - [Precision CKM Care: Allocate Capital to the Pathway Gap, Not Just the Risk Score](https://azisdabas.com/insights/precision-ckm-equity-pathway-allocation/) — 2026-10-07: A thesis for cardiovascular-kidney-metabolic care: combine clinical risk, access barriers and pathway capacity to allocate prevention investment more precisely. - [Post-acute capacity is an episode portfolio](https://azisdabas.com/insights/post-acute-capacity-portfolio-contracting/) — 2026-10-07: I examine home health and skilled nursing transitions through patient fit, usable capacity, medication continuity and episode contracting. - [Medicaid eligibility is becoming a continuity strategy](https://azisdabas.com/insights/medicaid-eligibility-continuity-economics-2027/) — 2026-10-07: Medicaid eligibility changes, coverage continuity and exemption evidence: a payer-provider strategy for auditable assistance and timely care. - [Imaging AI Economics: The Investment Case Runs from Detection to Completed Treatment](https://azisdabas.com/insights/imaging-ai-detection-treatment-pathway-economics/) — 2026-10-07: Imaging AI investment through mammography evidence, diagnostic capacity, patient follow-through and the economics of completed treatment pathways. - [Genomic Kidney Care: Invest in Decision Yield, Not Test Volume](https://azisdabas.com/insights/genomic-kidney-care-decision-yield/) — 2026-10-07: A business thesis for kidney genetics: turn diagnostic yield into supported treatment, family counseling and referral decisions with accountable follow-through. - [GLP-1 Cardiorenal Economics: Underwrite the Treatment Pathway Before the Outcome Contract](https://azisdabas.com/insights/glp1-cardiorenal-outcome-contract-economics/) — 2026-10-07: An executive framework for GLP-1 cardiorenal investment: distinguish clinical benefit, drug budget impact, persistence and credible outcome contracts. - [Food-as-Medicine Contracts Should Buy Nutritional Persistence, Not Enrollment](https://azisdabas.com/insights/food-as-medicine-contracting-persistence-evidence/) — 2026-10-07: A contracting framework for food-as-medicine programs that connects nutrition delivery, clinical follow-up, persistence and credible economic evaluation. - [Drug Shortage Resilience Is a Capital Allocation Decision](https://azisdabas.com/insights/drug-shortage-resilience-capital-allocation/) — 2026-10-07: A capital-allocation framework for medicine supply: evaluate clinical exposure, correlated suppliers, buffer inventory and the cost of continuity. - [Digital Quality Measurement Is Contracting Infrastructure: Build the Evidence Before the Score](https://azisdabas.com/insights/digital-quality-measurement-contracting-infrastructure/) — 2026-10-07: FHIR quality measurement as contracting infrastructure: govern denominators, evidence, revision rules and the cost of reproducible performance reporting. - [Cell and Gene Therapy Readiness: Financing the Complete Care Pathway](https://azisdabas.com/insights/cell-gene-therapy-readiness-financing-pathway/) — 2026-10-07: A cell and gene therapy readiness thesis connecting clinical delivery, Medicaid contracting, center liquidity, patient support and outcome obligations. - [Biosimilar Strategy: Capture Value Across the Benefit and the Clinic](https://azisdabas.com/insights/biosimilar-benefit-design-procurement-economics/) — 2026-10-07: Biosimilar procurement and benefit economics: reconcile payer savings, provider contribution, patient liability and the cost of changing treatment pathways. - [AI Clinical Trial Recruitment: Build Representative Enrollment, Not a Larger Eligibility Queue](https://azisdabas.com/insights/ai-clinical-trial-recruitment-representative-capacity/) — 2026-10-07: An investment framework for AI trial recruitment: align representative enrollment, site capacity, coordinator funding and cost per retained participant. - [Who creates value—and who gets to keep it?](https://azisdabas.com/insights/healthcare-market-structure-value-capture/) — 2026-09-27: Healthcare strategy begins with the distribution of power: who controls access, who sets the economic terms, who bears the risk and who can credibly choose another path. - [What recent research changes about healthcare strategy.](https://azisdabas.com/insights/recent-research-healthcare-strategy/) — 2026-09-27: An original executive synthesis of 2025–2026 scholarship on payer-provider integration, population health, value-based care and clinical AI. - [The therapy has to reach the person.](https://azisdabas.com/insights/pharmacy-whole-care-infrastructure/) — 2026-09-27: Pharmacy belongs at the center of whole-care design: connecting an appropriate treatment decision to access, safe use, monitoring and a sustainable economic model. - [The target variable is a resource-allocation decision.](https://azisdabas.com/insights/algorithmic-bias-allocation-target/) — 2026-09-27: A foundational algorithm audit shows why a model can predict spending accurately while directing care-management resources away from people with greater need. - [The signal is not the social need.](https://azisdabas.com/insights/wireless-sensing-whole-care-evidence/) — 2026-09-27: A framework for Wi-Fi and radio sensing in connected care: validated measurement, confirmed context, consent and an accountable response. - [The referral needs somewhere to go.](https://azisdabas.com/insights/social-care-public-health-infrastructure/) — 2026-09-27: My social-care framework connects person-defined needs, available services, community-partner economics and the distribution of benefit. - [The Postpartum Handoff Is a Business Model: Pay for Continuity Beyond Delivery](https://azisdabas.com/insights/postpartum-care-continuity-business-case/) — 2026-09-27: A postpartum-care business case built around completed handoffs, blood-pressure follow-up and continuing care, with long-term savings treated as uncertain. - [Productivity becomes value only when the operating model changes.](https://azisdabas.com/insights/ai-productivity-value-capture/) — 2026-09-27: Workplace evidence suggests that AI can spread useful expertise unevenly. Healthcare leaders still need to demonstrate how that benefit survives review, handoffs and the commercial contract. - [Precision Oncology’s Next Investment Is the Pathway Between the Report and Treatment](https://azisdabas.com/insights/precision-oncology-treatment-pathway/) — 2026-09-27: A precision-oncology investment thesis focused on the gaps between testing, interpretation, patient discussion and feasible treatment. - [Pharmacy value depends on the barrier being removed.](https://azisdabas.com/insights/pharmacy-access-incremental-value/) — 2026-09-27: A recent discharge trial and a foundational coverage trial show why medication access, transition safety and utilization savings need distinct investment cases. - [Own the unresolved handoff.](https://azisdabas.com/insights/whole-care-orchestration-strategy/) — 2026-09-27: My whole-care framework connects clinical care, pharmacy, behavioral health, social support and financing through accountable handoffs. - [Optimize for population benefit, not the visible cost curve.](https://azisdabas.com/insights/population-health-allocation-public-value/) — 2026-09-27: I examine population-health allocation through unmet need, intervention benefit, delivery capacity and the people poorly represented in claims. - [Obesity Pharmacotherapy Is Becoming a Continuity Business](https://azisdabas.com/insights/obesity-care-continuity-economics/) — 2026-09-27: What obesity treatment evidence means for payer and pharmacy strategy: continuity, patient burden and total episode cost beyond prescription volume. - [Kidney Prevention Belongs in the Capital Plan Before the Next Dialysis Expansion](https://azisdabas.com/insights/kidney-prevention-capital-allocation/) — 2026-09-27: A kidney-care capital framework for funding risk identification and prevention while preserving dialysis capacity and testing the economics. - [Integration should earn its place at the handoff.](https://azisdabas.com/insights/integrated-networks-episode-economics/) — 2026-09-27: Hospital-operated Medicare Advantage evidence shows why network strategy needs an episode-level account of utilization, outcomes and the value of ownership. - [Integration is a clinical operating model.](https://azisdabas.com/insights/behavioral-health-population-operating-model/) — 2026-09-27: A population approach to behavioral health connects access, treatment, systematic follow-up and clinical authority—and funds the work between appointments. - [Hospital at Home Must Buy Community Capacity Before It Can Release Hospital Capacity](https://azisdabas.com/insights/hospital-at-home-community-capacity/) — 2026-09-27: Hospital-at-home investment depends on reliable community capacity and a credible plan to convert released hospital capacity into value. - [Dementia Care Needs a Capacity Contract: Finance the Household, Not Just the Referral](https://azisdabas.com/insights/dementia-care-household-capacity/) — 2026-09-27: A dementia-care investment thesis connecting household support, reliable response capacity, family time and the distinction between value and savings. - [Capital should buy evidence before it buys permanence.](https://azisdabas.com/insights/healthcare-capital-allocation-under-uncertainty/) — 2026-09-27: An investment thesis becomes useful when it specifies which uncertainty to resolve, what commitment to make now and what evidence earns the next allocation. - [Behavioral-health integration needs a plan for month thirteen.](https://azisdabas.com/insights/behavioral-health-maintenance-evidence/) — 2026-09-27: Longer follow-up from a collaborative-care trial shifts the operating question from initial engagement to sustained improvement and a practical route back into treatment. - [Ambient AI needs a workflow-specific purchase decision.](https://azisdabas.com/insights/ambient-ai-evidence-procurement/) — 2026-09-27: A randomized scribe trial makes the buying question more precise: which tool improves which part of the work, for which clinicians, at what total cost? - [AI creates capacity. Strategy determines its value.](https://azisdabas.com/insights/healthcare-ai-value-capture-strategy/) — 2026-09-27: The enterprise case begins after a task gets faster: what changes in care, whose work remains, which costs disappear and who retains the economic benefit. - [A shared-savings payment is not the same as value created.](https://azisdabas.com/insights/value-based-care-underwriting-economics/) — 2026-09-27: Underwrite patient outcomes, provider economics and payer spending separately. Then reconcile the contract, the counterfactual and the cash required to sustain care. - [A longer savings horizon still needs an access test.](https://azisdabas.com/insights/value-based-care-long-horizon-equity/) — 2026-09-27: Longitudinal ACO evidence supports patient capital, while leaving leadership responsible for quality, equitable access and the participant's own economics. - [A larger training set does not validate every home.](https://azisdabas.com/insights/radar-sleep-evidence-transfer/) — 2026-09-27: Recent sleep research illustrates the distance between respiratory-model performance, radar measurement and a dependable home-care service. - [A benefit offer is only the beginning of an intervention.](https://azisdabas.com/insights/social-care-benefit-uptake-trial/) — 2026-09-27: A produce-prescription trial sharpens the investment case for social care: define benefit uptake, delivery costs and the outcome being purchased. - [After the AI Pilot: Who Owns the Healthcare Operating Model?](https://azisdabas.com/insights/healthcare-ai-operating-model-after-the-pilot/) — 2026-09-05: A whole-system reading of AI adoption, pharmacy access, interoperability, capital, and human oversight. The next mandate is an operating journey, not another isolated pilot. - [The Healthcare AI Control Plane: Designing the Whole System](https://azisdabas.com/insights/healthcare-ai-control-plane-whole-system/) — 2026-09-01: An executive architecture connecting healthcare data, workflows, payment, agents and human authority around accountable decisions and delivered care. - [The Healthcare AI Value Realization Ledger](https://azisdabas.com/insights/healthcare-ai-value-realization-ledger/) — 2026-08-11: Measure healthcare AI value after implementation, human review, exceptions and transferred workload, with explicit cash and capacity reconciliation. - [The ACCESS Model Turns Digital Health Into Reimbursed Care Infrastructure](https://azisdabas.com/insights/cms-access-model-healthtech-reimbursement/) — 2026-07-19: An operating analysis of the CMS ACCESS Model: chronic-care delivery, outcome measurement and the demands of Medicare reimbursement. - [The 2027 Physician Fee Schedule Makes Provider Economics a Product Requirement](https://azisdabas.com/insights/2027-physician-fee-schedule-provider-economics/) — 2026-07-19: A provider-economics analysis of the proposed 2027 fee schedule: segment payment models, price implementation and test how practices capture value. - [Telehealth Extension Gives FQHCs Time to Build a Better Hybrid Care Model](https://azisdabas.com/insights/fqhc-telehealth-hybrid-care-model/) — 2026-07-19: An FQHC strategy linking telehealth to hybrid access, behavioral-health capacity, completed referrals and longitudinal patient care. - [Software as a Medical Service Changes the Reimbursement Conversation](https://azisdabas.com/insights/software-as-medical-service-reimbursement/) — 2026-07-19: I assess proposed software-as-medical-service reimbursement through incremental value, collection economics, policy uncertainty and alternative commercial routes. - [Kidney Payment Reform Still Depends on Referral and Intake Operations](https://azisdabas.com/insights/kidney-care-referral-intake-operations/) — 2026-07-19: How referral, education, intake, modality choice and clinical handoffs determine whether kidney-care payment models can deliver coordinated care. - [Interoperability Is Becoming Commercial Distribution Infrastructure](https://azisdabas.com/insights/interoperability-commercial-distribution/) — 2026-07-19: Evaluate healthcare interoperability through reusable implementation, accountable data-to-action workflows and the cost of ongoing reconciliation. - [Healthtech Capital Is Buying Operating Leverage, Not AI Labels](https://azisdabas.com/insights/healthtech-capital-operating-leverage/) — 2026-07-19: A healthtech investment framework connecting technology to distribution, workflow adoption, measurable value and repeatable economics. - [Healthcare AI Product Strategy Starts With the Regulatory Boundary](https://azisdabas.com/insights/healthcare-ai-regulatory-boundary/) — 2026-07-19: How healthcare software teams can define intended use, clinical review and evidence requirements before making regulatory and product decisions. - [Healthcare AI Buyers Will Test the Claim, Not the Demo](https://azisdabas.com/insights/healthcare-ai-claims-buyer-diligence/) — 2026-07-19: A buyer framework for evaluating healthcare AI performance, autonomy and savings claims through evidence, limitations, ownership and monitoring. - [Health-App Data Governance Is Part of the Commercial Product](https://azisdabas.com/insights/health-app-data-governance-commercial-trust/) — 2026-07-19: Health-data permissions create operating obligations. Evaluate vendor dependencies, enforceable user choices and the full cost of each data flow. - [AI Voice Is Moving Inside the RCM System of Record](https://azisdabas.com/insights/ai-voice-rcm-system-of-record/) — 2026-07-19: An operating case for AI voice in revenue cycle: connect payer calls, authorization and claim follow-up to review, evidence and financial results. - [340B Is Becoming a Claims-Data Operating Problem](https://azisdabas.com/insights/340b-claims-data-operating-system/) — 2026-07-19: How proposed Part D claim-level requirements connect 340B pharmacy operations, finance, traceability, contract pharmacies and rebate workflows. - [What a Healthcare AI Consultant Should Actually Build](https://azisdabas.com/insights/healthcare-ai-consulting-operating-model/) — 2026-07-16: How to scope healthcare AI consulting around transferable capability, lifecycle economics, operating ownership and evidence for continued investment. - [How Health Plans Should Evaluate AI-Native and Rules-Based Payment Integrity Vendors](https://azisdabas.com/insights/health-plans-evaluate-ai-payment-integrity-vendors/) — 2026-07-16: A payer framework for payment-integrity vendors: savings quality, explainability, provider friction, appeals, governance and implementation cost. - [Agentic Revenue Integrity Needs a Control Plane](https://azisdabas.com/insights/agentic-revenue-integrity-control-plane/) — 2026-07-16: An architecture for revenue integrity across authorization, claims, denials and payment review, with accountable human decisions and financial evidence. - [Care Orchestration Contracts: Separate Delivery from Claimed Savings](https://azisdabas.com/insights/2026-06-19-healthtech-pulse/) — 2026-06-19: Structure care-orchestration contracts around funded delivery, credible comparators and savings claims that survive scrutiny of the denominator. - [Healthcare Investment Diligence: Test the Promise Against Delivery](https://azisdabas.com/insights/2026-06-18-healthtech-pulse/) — 2026-06-18: Healthcare investment diligence should connect network promises, reimbursement assumptions and integration claims to delivery and collectible cash. - [Healthcare Navigation: Underwrite the Transition](https://azisdabas.com/insights/2026-06-17-healthtech-pulse/) — 2026-06-17: Underwrite healthcare navigation and software replacement through resolved transitions, receiving capacity, migration cost and continuity. - [Administrative Access: Connect Coverage, Resolution and Cash](https://azisdabas.com/insights/2026-06-16-healthtech-pulse/) — 2026-06-16: Connect healthcare coverage, billing resolution and cash conversion while testing vendor-reported AI results against local operating conditions. - [Provider AI Economics: Distinguish Productivity from Payment Transfer](https://azisdabas.com/insights/2026-06-14-healthtech-pulse/) — 2026-06-14: Provider AI economics require separate accounts for productivity, reimbursement and patient benefit, with payer response and evidence limits visible. - [Payment Disputes and Care Coordination: The Cost of Resolution](https://azisdabas.com/insights/2026-05-28-healthtech-pulse/) — 2026-05-28: Payment-dispute reform changes pursuit economics. Assess net recovery, eligible workload and the cost of resolving coordination failures. - [Prior Authorization Is Becoming API Infrastructure](https://azisdabas.com/insights/prior-authorization-api-infrastructure/) — 2026-05-26: I distinguish prior-authorization API compliance from workflow value, tracing request completion, exception cost and payer-provider workload. - [Payment Integrity Is Moving From Audit Function to AI Operating Layer](https://azisdabas.com/insights/payment-integrity-ai-operating-layer/) — 2026-05-26: I evaluate payment-integrity AI through substantiated decisions, net retained value, appeal outcomes, contract incentives and provider burden. - [Healthcare AI Search Is Changing Buyer Discovery](https://azisdabas.com/insights/healthcare-ai-search-buyer-discovery/) — 2026-05-26: Build healthcare discovery around original analysis, attributable experience and accessible evidence that helps buyers evaluate a commercial position. - [Agentic RCM Needs Governance, Not More Automation Claims](https://azisdabas.com/insights/agentic-rcm-governance/) — 2026-05-26: A financial governance framework for agentic revenue cycle: allocate authority, price review and reconcile recovered revenue separately from faster collection. - [Automated Healthcare Administration: The Economics of Verification](https://azisdabas.com/insights/2026-05-23-healthtech-pulse/) — 2026-05-23: Evaluate automated healthcare administration through the cost of processing, substantiating, contesting and correcting a transaction. - [Healthcare AI Infrastructure: Price the Responsibilities That Remain](https://azisdabas.com/insights/2026-05-22-healthtech-pulse/) — 2026-05-22: Healthcare AI infrastructure requires a full account of deployment, workflow maintenance, decision authority and recovery responsibilities. - [Benefits AI: Reliable Identity, Coverage and the Next Action](https://azisdabas.com/insights/2026-05-21-healthtech-pulse/) — 2026-05-21: Benefits AI depends on reliable identity, current coverage and feasible services. Assess resolution, escalation and barriers to legitimate access. - [Healthcare Platform Growth: Which Costs Actually Fall with Scale?](https://azisdabas.com/insights/2026-05-20-healthtech-pulse/) — 2026-05-20: Compare healthcare platform and clinical-service growth through coordination costs, delivery obligations, payer economics and retained margin. - [Coverage Volatility: The Cost of Acting on Stale Information](https://azisdabas.com/insights/2026-05-19-healthtech-pulse/) — 2026-05-19: Coverage volatility creates costly decisions from stale information. Fund reconciliation while preserving care continuity and patient access. - [Electronic Authorization: Finance Reliability and the Right to Challenge](https://azisdabas.com/insights/2026-05-17-healthtech-pulse/) — 2026-05-17: Electronic authorization requires shared responsibility, reliable exchange and a funded route to challenge and correct consequential decisions. - [Claims Intelligence: From Flagged Exposure to Collectible Cash](https://azisdabas.com/insights/2026-05-16-healthtech-pulse/) — 2026-05-16: Turn claims intelligence into defensible recovery and contract decisions by separating flagged exposure, probable recovery and collectible cash. - [Prior Authorization Readiness: The Economics of the Remaining Work](https://azisdabas.com/insights/2026-05-14-healthtech-pulse/) — 2026-05-14: Evaluate prior authorization readiness through remaining case complexity, exception handling, supplier incentives and total administrative cost. - [From Policy Signal to Funded Operating Decision](https://azisdabas.com/insights/2026-05-12-healthtech-pulse/) — 2026-05-12: Separate policy requirements, recommendations and pledges to identify funded healthcare buyers and feasible operating investments. - [Trust in Healthcare: Allocate Responsibility Before Automation](https://azisdabas.com/insights/2026-05-11-healthtech-pulse/) — 2026-05-11: A healthcare trust framework connecting decision authority, evidence, correction and the service costs behind automation and medication access. - [Clinical Information and Distribution: Who Controls the Decision?](https://azisdabas.com/insights/2026-05-10-healthtech-pulse/) — 2026-05-10: Clinical search and information exchange change distribution. Evaluate evidence quality, accountable decisions and dependence on intermediaries. - [Healthcare Integration: Where Control Justifies the Cost](https://azisdabas.com/insights/2026-05-09-healthtech-pulse/) — 2026-05-09: A healthcare integration thesis: compare ownership with partnership through coordination costs, clinical responsibility and switching risk. - [Drug Access, Patient AI and Data: Price the Unresolved Work](https://azisdabas.com/insights/2026-05-08-healthtech-pulse/) — 2026-05-08: An operating analysis of temporary drug access, patient-facing AI and healthcare data, with the cost of unresolved work made explicit. - [Prior Authorization Reform: Underwrite a Smaller, More Complex Workload](https://azisdabas.com/insights/2026-05-07-healthtech-pulse/) — 2026-05-07: Prior authorization reform changes request volumes and complexity. Underwrite residual workload, vendor incentives and reliable resolution. - [Healthcare Technology Investment: Follow the Constraint and the Cash](https://azisdabas.com/insights/2026-05-06-healthtech-pulse/) — 2026-05-06: A healthcare investment framework connecting pathway constraints, access capacity, payment incentives and the value a buyer can retain. - [Payers Enter the AI-and-Access Era](https://azisdabas.com/insights/payers-enter-the-ai-and-access-era/) — 2026-04-27: I examine payer technology investments through case resolution, cost transfers, member access and the conditions under which operational gains become value. - [The Orchestration Imperative](https://azisdabas.com/insights/the-orchestration-imperative/) — 2026-03-10: I examine orchestration as an investment in reliable care commitments, distinguishing information gaps from capacity, authority and funding failures. - [CMS ACCESS Model and New York Healthcare](https://azisdabas.com/insights/cms-access-model-new-york-healthcare/) — 2026-01-06: A New York ACCESS strategy built around accountable referral corridors, separate payment routes, clinical delivery capacity and cohort-level contribution economics. - [Why New York Hospitals Are Building Digital Twins](https://azisdabas.com/insights/new-york-hospitals-digital-twins/) — 2025-11-22: Evaluate healthcare digital twins against simpler alternatives, response capacity, social-context validity and the incremental value of better decisions. - [Game Theory, AI, Machine Learning, and LLMs](https://azisdabas.com/insights/game-theory-ai-llms-strategy/) — 2025-09-25: An incentive-based analysis of healthcare AI: counterparty responses, information asymmetry and contracts determine whether local productivity becomes system value. - [Value-Based Care GTM](https://azisdabas.com/insights/value-based-care-gtm/): I connect value-based care commercialization to buyer risk, contract settlement, delivery obligations, evaluation horizons and the cash required to sustain care. - [The CFO Economics of Accountable Access](https://azisdabas.com/insights/cfo-economics-accountable-access/): A CFO framework for medical margin, risk, capital allocation and enterprise value in New York’s accountable-care market, 2026–2030. - [Specialty Pharmacy Commercialization](https://azisdabas.com/insights/specialty-pharmacy-commercialization/): I examine specialty-pharmacy commercialization through therapy economics, payer access, working capital, operating controls and the durability of the asset. - [Series A Healthtech GTM Strategy](https://azisdabas.com/insights/series-a-healthtech-gtm-strategy/): I assess Series A healthtech growth through customer-cohort economics, implementation capacity, cash payback and the conditions for adding sales investment. - [Provider Network Growth Strategy](https://azisdabas.com/insights/provider-network-growth-strategy/): I examine provider-network growth through referral economics, receiving capacity, concentration risk and the investment required to turn relationships into care. - [Proof-Led Growth in Regulated Healthcare](https://azisdabas.com/insights/regulated-healthcare-growth-proof/): I examine how healthcare companies sequence evidence and capital, test transferability and set defensible thresholds for deployment and commercial expansion. - [Payer Strategy for Healthtech Founders](https://azisdabas.com/insights/payer-strategy-for-healthtech-founders/): Payer commercialization through attribution, contracting economics and evidence: identify who retains the benefit and who funds its delivery. - [HubSpot for Healthcare RevOps](https://azisdabas.com/insights/hubspot-healthcare-revops/): Design HubSpot around accountable referral handoffs, authoritative systems and cohort economics that guide healthcare budget and staffing decisions. - [Healthcare RevOps and Practical AI](https://azisdabas.com/insights/healthcare-revops-ai/): Healthcare revenue operations: connect demand, completed services and collected contribution, then test where AI improves allocation. - [Healthcare GTM Operating System](https://azisdabas.com/insights/healthcare-gtm-operating-system/): A healthcare growth framework linking customer cohorts, implementation capacity, collected contribution and working capital to the next allocation. - [Healthcare AI Go-to-Market](https://azisdabas.com/insights/healthcare-ai-go-to-market/): Healthcare AI commercialization: align budget authority, implementation ownership and evidence of buyer value before scaling a repeatable offer. - [Fractional Head of GTM for Healthcare](https://azisdabas.com/insights/fractional-head-of-gtm-healthcare/): When fractional commercial leadership is worth funding: resolve market uncertainty, test repeatability and define the authority and timing of a permanent hire. - [Claims Intelligence and Referral Leakage](https://azisdabas.com/insights/claims-intelligence-referral-leakage/): A framework for separating observed referral leakage from recoverable demand, testing incremental contribution and allocating field resources against care capacity.